Febrile neutropenia (FN) is a common and serious complication of cytotoxic chemotherapy. It impairs the immune system, placing the cancer patient at risk of infection and is a key contributor to chemotherapy-associated morbidity and mortality. Factors including therapeutic regimen, tumour type and individual characteristics influence susceptibility to myelosuppression. Over the years, several granulocyte-colony stimulating factors (G-CSFs) have been developed for primary prophylaxis of FN including filgrastim, lenograstim and pegfilgrastim. These agents have demonstrated safety and efficacy in reducing FN in patients allowing for administration of optimal treatment and thereby improving clinical outcomes. They also support the use of dose-dense and dose-intense chemotherapy regimens found to be beneficial in some patients. Recently, the introduction of biosimilars of G-CSFs with proven comparability with the originator filgrastim has expanded the prophylactic therapies available. Effective use of these drugs by physicians early in the chemotherapy schedule may lead to fewer adverse events and improved survival.
presence of comorbidities in subjects. In those without any major comorbidity the mortality rate was 2.6 %, whereas this value increased to 10.3 and >21 % in patients with one and more than one major comorbidity, respectively. Moreover, in the systemic use of chemotherapy, myelosuppression and its subsequent complications are the most common dose-limiting toxicities. As such, FN can have a substantial impact on the ability to deliver full-dose chemotherapy on schedule imposing a significant burden and challenge to oncologists. 5, 6 This may increase the risk of disease recurrence and disease-related mortality, especially in those individuals where reduction of dose or density of treatment is associated with poor prognosis. FN may also result in longer hospital stays and increased monitoring, diagnostic and treatment costs while reducing quality of life.
Neutropenia is often avoidable and this would reduce hospital admissions, antibiotic usage and the need for dose reductions and delays in chemotherapy administration. 6 Effective management of FN embraces prevention of the condition with prophylactic measures, such as the use of granulocyte colony-stimulating factor (G-CSF) as well as the appropriate management of FN and FN-related events as they occur. It may also be feasible to lower the dose or frequency of therapy to control the incidence of asymptomatic neutropenia and FN. In this article, an up-to-date review of the use of G-CSF for the prevention of chemotherapy-induced FN is provided.
Definition and Risk Factors
In healthy individuals, the lower limit of the blood neutrophil count is approximately 2,000 cells/mm 3 . Values below this indicate neutropenia and are classified according to severity where 1,500-2,000 cells/mm 3 is grade 1 neutropenia, 1,000-1,500 cells/mm 3 grade 2, 500-1,000 cells/mm 3 grade 3 and <500 cells/mm 3 is grade 4, the most severe. 7 More specifically, FN is defined as a rise in body temperature to >38.0°C for a duration of >1 hour or a single temperature reading of >38.5°C, while having an absolute neutrophil count of <500/mm 3 .
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The intensity (including the frequency and/or total dose) of a chemotherapy regimen is a primary determinant of risk for neutropenia and some regimens are more myelosuppressive than others. 10 For example, doxorubicin plus docetaxel in patients with metastatic breast cancer has been associated with a high risk of FN. 11, 12 Similarly, patients with non-Hodgkin's lymphoma (NHL) that are treated with high doses of cyclophosphamide or etoposide are more likely to develop FN. 13, 14 The same outcome is observed with high doses of anthracycline in early breast cancer patients. 15 The type of tumour may also be a predictor of FN. Patients with haematological malignancies are at greater risk of experiencing FN than those with solid tumours owing to the nature of the underlying disease process and the intensity of the required treatment. 16 However, after controlling for the type of cancer, advanced and uncontrolled diseases are significant predictors of neutropenic complications. 16, 17 Aside from factors relating to the cancer and its treatment, patient 
Granulocyte-colony Stimulating Factor
One method by which to manage FN is through the use of haematopoietic growth factors such as G-CSF. These agents work to stimulate haematopoietic progenitors thereby increasing the number of functional neutrophils. 23 A recombinant human G-CSF, filgrastim (Neupogen ® ), was first purified from human cell lines and placenta, and cloned in the mid-1980s. [24] [25] [26] Similarly, randomised controlled trials of lenograstim [34] [35] [36] and pegfilgrastim 9,37,38 have provided substantial evidence that their prophylactic use reduces the incidence of chemotherapy-induced FN.
Several high-quality meta-analyses, in haematological malignancies and solid tumours, support the use of G-CSF to prevent chemotherapy-induced FN. [39] [40] [41] Indeed, G-CSF use has been shown to be effective in accelerating neutrophil recovery in patients with acute
Prophylactic Granulocyte-colony Stimulating Factor for Chemotherapy-induced Febrile Neutropenia Here, patients were randomised to receive either VAPEC-B (vincristine, Adriamycin ® , prednisolone, etoposide, cyclophosphamide and bleomycin) therapy alone or therapy with G-CSF administered subcutaneously daily. Figure 2 illustrates the finding that subjects using G-CSF had a lower percentage reduction in dose intensity relative to controls.
Similarly, a recent prospective observational study in patients with breast cancer or lymphoma showed that FN was associated with low relative dose intensity chemotherapy (i.e. reductions and/or delays)
for both malignancies. 55 Prophylactic G-CSF in turn had a strong protective effect against dose modifications in lymphoma patients.
Finally, a systematic review and meta-analysis established that patients who received prophylactic G-CSF had significantly fewer dose reductions and delays in cytotoxic chemotherapy than those who received placebo or no supportive care. 41 
Support of Dose-dense and Dose-intense Chemotherapy Regimens
There are instances where an increased frequency or dose of chemotherapy is found to be beneficial. As a result, dose-dense or dose-intense regimens are increasingly being incorporated into the therapeutic algorithm by oncologists in an attempt to improve clinical outcomes in cancer patients. 56, 57 This approach is likely to be particularly relevant where treatment is intended to be curative or to lymphoma. 59 In a meta-analysis of seven lymphoma trials involving G-CSF, all but one study showed a higher dose intensity in the G-CSF-treated arm compared with the control arm. 40 
Effect of Prophylactic Granulocyte-colony Stimulating Factor use on Survival Outcomes
With the use of G-CSF reducing the incidence of FN and allowing optimal treatment, it is possible that this could result in improved survival outcomes. 41 Several meta-analyses have recently investigated this hypothesis with conflicting results. and all-cause early mortality by 40 % (3.4 versus 5.7 %; p=0.002). 41 The studies in this analysis consisted of relatively young and fit patient populations and an even larger benefit of G-CSF may be observed in older populations. By contrast, a meta-analysis using data from 148 studies of prophylactic G-CSF or granulocyte-macrophage
Supportive Oncology colony-stimulating factor (GM-CSF) in a wide range of settings showed little to no mortality benefit with CSFs compared with placebo or no treatment. 60 Similar results were reported in a Cochrane database review of 13 trials in patients with lymphoma. 40 This disparity may be attributed to the heterogeneity of the studies analysed. Furthermore, the two meta-analyses showing no effect on mortality endpoints included studies of GM-CSF, which is thought to be less effective than G-CSF at reducing FN.
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Comparisons Between Different Formulations of Granulocyte-colony Stimulating Factor
Filgrastim and Lenograstim
Evidence from a meta-analysis suggests that filgrastim and lenograstim have comparable efficacy with regards to FN and FN-related endpoints. 39 Eight studies of prophylactic G-CSF In order for biosimilars to be approved, they must undergo numerous trials that prove their similarity to the originator product in terms of efficacy and safety. A meta-analysis of three clinical studies involving a total of 608 breast cancer, lung cancer and NHL patients investigated the comparability of the G-CSF biosimilar XM02
with its originator filgrastim. 63 Patients were treated with prophylactic G-CSF during the first cycle of chemotherapy and the incidence of FN was determined. The collective results indicated the non-inferiority of XM02 relative to filgrastim with respect to the incidence of FN and this was seen regardless of the myelotoxicity of the chemotherapy regimen.
Similarly, the biosimilar EP2006 was evaluated in Phase I and III studies in healthy volunteers and neutropenic patients. 64 The studies in healthy volunteers confirmed the biosimilarity of EP2006 with its reference product filgrastim with regards to pharmacodynamics and
pharmacokinetics. The open Phase III study included 170 breast cancer patients undergoing four cycles of doxorubicin and docetaxel chemotherapy. Primary prophylaxis of severe neutropenia using EP2006 demonstrated its efficacy and safety. It was therefore concluded that this biosimilar had sufficient comparability with its originator filgrastim. 64 Hospira Filgrastim (Nivestim  TM ) A further biosimilar molecule developed by Hospira based on the originator filgrastim was approved in June 2010. A study was designed to evaluate the similarities of this Hospira filgrastim with the reference filgrastim from Amgen. 65 This was an extensive characterisation study that assessed and compared the physiochemical properties of the two products. Both drugs were evaluated using state-of-the-art analytical methods and no significant differences were found regarding their physiochemical properties, molecular characteristics, purity and biological activity.
Furthermore, when subjected to stress conditions (storage at 40º C), product-related impurities were similar between the two drugs for up to 12 weeks. 65 However, in terms of stability, Hospira filgrastim has an out of refrigerator stability of up to seven days allowing it to be used in an ambulatory setting, whereas Amgen filgrastim can only be left at room temperature for a maximum of 24 hours before it must be discarded. This suggests an improvement in the quality of product available in later generation formulations while retaining the fundamental biological aspects.
Additional Phase I and III studies further support the equivalence of the Hospira filgrastim and Amgen filgrastim in healthy volunteers and 282 patients with breast cancer. [66] [67] [68] These randomised trials demonstrated that Hospira filgrastim was comparable in pharmacokinetic properties, pharmacodynamic profile, efficacy and safety to filgrastim.
Pegfilgrastim
With its approval in 2002, pegfilgrastim had overtaken filgrastim as the standard of care for cancer patients undergoing chemotherapy owing to its convenient dosing schedule. As its name suggests, pegfilgrastim is pegylated and therefore has a longer half-life than filgrastim within the body. As a result, only a single dose of pegfilgrastim is required per cycle of chemotherapy versus daily filgrastim injections. A meta-analysis of five studies with a total of 617 patients receiving myelosuppressive therapy was conducted to investigate the relative efficacies of pegfilgrastim and filgrastim. 69 The pooled findings of the trials suggest that one dose of pegfilgrastim is significantly more effective at reducing the rate of FN in patients than a median of 10-14 days of filgrastim (pooled relative risk of 0.64; 95 % CI, 0.43-0.97).
Similarly, the rate of grade 4 neutropenia was also significantly reduced using pegfilgrastim compared with filgrastim. While these findings may reflect the sustained activity of pegfilgrastim, trial heterogeneity was an acknowledged limitation of this meta-analysis and may have influenced the results. The trials included varied in the type of cancer, chemotherapy regimen and trial design. 69 At present, biosimilars of pegfilgrastim are in development and will soon be entering the market.
Current Use of Prophylactic Granulocyte-colony Stimulating Factor for Chemotherapy-induced Febrile Neutropenia
With the number of G-CSF products available, it is important to develop comprehensive guidelines to ensure consistency in their application across different institutions and that all appropriate patients are considered for these drugs. Prior to 2006, primary G-CSF prophylaxis was only recommended for cancer patients receiving chemotherapy regimens associated with a 40 % risk of FN or higher. 70 However, later evidence suggested a clinical benefit at much lower levels of risk. Data showed that G-CSF prophylaxis confers positive results to patients with a FN risk of 20 % or higher. G-CSF should also be used to support dose-dense or dose-intense chemotherapy as well as to help maintain the dose intensity or dose density of standard regimens, especially when the treatment intent is curative or to prolong survival. 1 Despite these guidelines, in real-world clinical practice settings, patients often receive inconsistent and suboptimal courses of G-CSF treatment highlighting the need for better knowledge of these recommendations.
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Summary and Conclusions
Over the years, several G-CSF drugs have been developed that have shown efficacy in preventing FN in cancer patients receiving myelosuppressive chemotherapy. Recent introductions of biosimilar products have expanded the choices available to clinicians. Proper administration of these treatments to appropriate individuals will help reduce the incidence of FN, thereby promoting optimal therapy and better prognosis. Moreover, this will likely result in cost savings for healthcare systems, as the number of complications will be reduced. It therefore becomes important that physicians and patients are aware of these products and their potential benefits in cancer treatment. n
